Clinical trials of FDA approved proteasome inhibitors, which are also NF-κB inhibitors, in combination with other therapeutic drugs for the treatment of patients with AML are ongoing [60,61,62,63]. The gene discussed is NFKB1; the disease is acute myeloid leukemia.